| Management target | Revenue 2032 |
|---|
| Revenue growth | 13% p.a. revenue growth from FY24 to FY26. |
|---|---|
| Margins | EBITDA margins rising significantly post-merger due to synergies. |
| Demand visibility | Strong; backed by 150+ country presence and patent cliffs. |
| Management confidence | High; aiming for top 10 global animal health player. |
Growth
FY26 revenue reached INR 34,203 Mn (13% CAGR) with EBITDA at INR 7,025 Mn showing significant margin expansion (60% CAGR).
Outlook
2032 Aspiration: ~$1Bn Revenue, ~$250Mn EBITDA, and 25%+ ROCE. Targeting 20%+ growth in CDMO segment.
Risks
Regulatory compliance at 16 facilities and successful integration of the Bio For Life Italy acquisition.
Last quarter's promises, checked
Delivered
- Guided 20% EBITDA margin → delivered 20.5% (= BEAT)
- Targeted INR 50-60Cr merger synergies → delivered ~INR 60Cr annualized (= BEAT)
- Guided animal health API growth → delivered INR 400Cr run rate from INR 350Cr (= BEAT)
Partly delivered
- Guided FY26 Revenue INR 3,500Cr+ → delivered INR 3,420Cr (= PARTIAL)
Earnings Call filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹244.35
- Market cap
- ₹10,791 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 63.0×Sector 50.4×
- Promoter holding
- 61.31%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.
Viyash Scientific Merger & Restructuring
Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.
Viyash Scientific Acquisition
Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.
Viyash Scientific Employee Stock Options
Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.
- Call
- Guides 18% growth
Viyash Scientific Earnings Call Transcript: Key Takeaways
Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.
- Call
- Guides 18% growth